117 related articles for article (PubMed ID: 9397201)
21. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy.
Murphy GP; Elgamal AA; Troychak MJ; Kenny GM
Prostate; 2000 Mar; 42(4):315-7. PubMed ID: 10679761
[TBL] [Abstract][Full Text] [Related]
22. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results.
Sodee DB; Ellis RJ; Samuels MA; Spirnak JP; Poole WF; Riester C; Martanovic DM; Stonecipher R; Bellon EM
Prostate; 1998 Nov; 37(3):140-8. PubMed ID: 9792131
[TBL] [Abstract][Full Text] [Related]
24. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
Kusuda Y; Miyake H; Kurahashi T; Fujisawa M
Urol Oncol; 2013 Jul; 31(5):615-21. PubMed ID: 21600799
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
[TBL] [Abstract][Full Text] [Related]
26. Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.
Gupta SK; Watson T; Denham J; Shakespeare TP; Rutherford N; McLeod N; Picton K; Ainsworth P; Bonaventura T; Martin JM
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):701-709. PubMed ID: 29280465
[TBL] [Abstract][Full Text] [Related]
27. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
[TBL] [Abstract][Full Text] [Related]
28. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
29. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers.
Sodee DB; Malguria N; Faulhaber P; Resnick MI; Albert J; Bakale G
Urology; 2000 Dec; 56(6):988-93. PubMed ID: 11113745
[TBL] [Abstract][Full Text] [Related]
30. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
[TBL] [Abstract][Full Text] [Related]
31. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
[TBL] [Abstract][Full Text] [Related]
32. Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence?
Adsan O; Cecchini MG; Bisoffi M; Wetterwald A; Klima I; Danuser HJ; Studer UE; Thalmann GN
BJU Int; 2002 Oct; 90(6):579-85. PubMed ID: 12230621
[TBL] [Abstract][Full Text] [Related]
33. PSA-based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors.
Reissigl A; Pointner J; Horninger W; Strasser H; Mayersbach P; Klocker H; Schönitzer D; Bartsch G
Prostate; 1997 Jan; 30(1):20-5. PubMed ID: 9018331
[TBL] [Abstract][Full Text] [Related]
34. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
[TBL] [Abstract][Full Text] [Related]
35. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
[TBL] [Abstract][Full Text] [Related]
36. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
[TBL] [Abstract][Full Text] [Related]
37. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
38. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
39. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
40.
Schmidkonz C; Hollweg C; Beck M; Reinfelder J; Goetz TI; Sanders JC; Schmidt D; Prante O; Bäuerle T; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Prostate; 2018 Jan; 78(1):54-63. PubMed ID: 29105797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
